Ovarian CancerNCT07642791
Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy.
A study testing Opportunistic salpingectomy and Cholecystectomy in people with Ovarian Cancer and Cholecystolithiasis, run by University of Zurich at 1 site in Switzerland.
Trial summary
The knowledge, coupled with epidemiological studies demonstrating lower ovarian cancer rates in women with a history of tubal sterilization has led to recommendations for opportunistic salpingectomy at the time of benign gynecological surgery. Read more about this study
- Who is it for?
- Ages 45 years and older, women only
- Conditions the study is for
- Ovarian Cancer, Cholecystolithiasis
- What is being tested?
- Opportunistic salpingectomy and Cholecystectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteSwitzerland
- Study dates
- 15 Apr 2026to 31 May 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women aged 45 years or older.
- No known history of ovarian or fallopian tube cancer.
- Completed family planning.
- Scheduled to undergo elective laparoscopic cholecystectomy for benign gallbladder disease.
- Able to provide informed consent.
- Willing to comply with study procedures and follow-up assessments.
Who cannot join
- Previous abdominal Surgery or any inflammatory bowel disease.
- Current pregnancy or breastfeeding (verbally asked).
- Contraindications to laparoscopic surgery (e.g., severe cardiopulmonary disease, extensive prior abdominal surgery).
- Any medical condition that, in the opinion of the investigator, would preclude safe participation in the study or interfere with follow-up.
- Participation in another clinical trial that may confound the results of this study.
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Division of Visceral Surgery and Transplantation , University Hospital Zurich
Zurich, 8091
About this study
Official title: Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy: A Randomized Controlled Trial
The knowledge, coupled with epidemiological studies demonstrating lower ovarian cancer rates in women with a history of tubal sterilization has led to recommendations for opportunistic salpingectomy at the time of benign gynecological surgery. However, this recommendation was not explored in the setting of non-gynecological surgeries, of most if the surgery performed not in pelvis.
This study aims to evaluate the safety of performing opportunistic salpingectomy at the time of elective laparoscopic cholecystectomy in women aged 45 years or older. Of note, the only available prospective study from Austria evaluated feasibility of combined operation. By assessing complication rates and other perioperative outcomes, the study seeks to determine if this combined approach is a safe for opportunistic ovarian cancer prevention. Ultimately, this research may inform surgical practice and potentially reduce the incidence of ovarian cancer in this population.
- Conditions
- Ovarian Cancer, Cholecystolithiasis
- Being tested
- Opportunistic salpingectomy, Cholecystectomy
- Medical subject headings
- Ovarian Neoplasms, Cholecystolithiasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Opportunistic salpingectomyProcedure or surgery
Opportunistic salpingectomy at the time of elective laparoscopic cholecystectomy will be performed in study group, while the control group undergo cholecystectomy without salpingectomy.
CholecystectomyProcedure or surgery
Cholezystectomy as controll group
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | Opportunistic salpingectomy during surgery. Receives: Procedure: Opportunistic salpingectomy; Procedure: Cholecystectomy |
| Control group | Active comparator | Elective cholecystectomy Receives: Procedure: Cholecystectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative complications assesed with Comprehensive complication index.
This will be the primary outcome measure, encompassing any complications assessed with Comprehensive Complication Index. The range between 0 and 100. The higher score means more complications.
Measured: within 6 weeks after surgery
Secondary outcomes (2)
Operating time
Operating time measured in minutes from incision until skin stich
Measured: Operating time in minutes during surgical procedure
Length of hospital stay
Length of hospital stay calculated in days
Measured: Length of hospital stay: The number of days patients remain hospitalized after surgery untill discharge assedd at discharge (assessed at around 5 days).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start15 Apr 2026
- Primary completion31 May 2028 (estimated)
- Study completion31 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Controlled Trial
- Masking
- None (open label)
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dilmurodjon MDE Eshmuminov, MD, Principal investigator, Univercity hospital zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07642791
- Sponsor's protocol ID
- 2026-00157
- Status last verified
- Jun 2026
- First submitted
- 17 Apr 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07642791
- Acronym / sponsor ID
- 2026-00157
- Conditions
- Ovarian Cancer, Cholecystolithiasis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 15 Apr 2026 (actual)
- Primary completion
- 31 May 2028 (estimated)
- Study completion
- 31 May 2029 (estimated)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The knowledge, coupled with epidemiological studies demonstrating lower ovarian cancer rates in women with a history of tubal sterilization has led to recommendations for opportunistic salpingectomy at the time of benign gynecological surgery. However, this recommendation was not explored in the setting of non-gynecological surgeries, of most if the surgery performed not in pelvis.
This study aims to evaluate the safety of performing opportunistic salpingectomy at the time of elective laparoscopic cholecystectomy in women aged 45 years or older. Of note, the only available prospective study from Austria evaluated feasibility of combined operation. By assessing complication rates and other perioperative outcomes, the study seeks to determine if this combined approach is a safe for opportunistic ovarian cancer prevention. Ultimately, this research may inform surgical practice and potentially reduce the incidence of ovarian cancer in this population.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized Controlled Trial
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Procedure: Opportunistic salpingectomy, Procedure: CholecystectomyOpportunistic salpingectomy during surgery. |
| Control group | Active comparator | Procedure: CholecystectomyElective cholecystectomy |
Who may qualify
- Ages
- 45 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Women aged 45 years or older.
- No known history of ovarian or fallopian tube cancer.
- Completed family planning.
- Scheduled to undergo elective laparoscopic cholecystectomy for benign gallbladder disease.
- Able to provide informed consent.
Key exclusion criteria (5 listed)
- Previous abdominal Surgery or any inflammatory bowel disease.
- Current pregnancy or breastfeeding (verbally asked).
- Contraindications to laparoscopic surgery (e.g., severe cardiopulmonary disease, extensive prior abdominal surgery).
- Any medical condition that, in the opinion of the investigator, would preclude safe participation in the study or interfere with follow-up.
- Participation in another clinical trial that may confound the results of this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Opportunistic salpingectomyOpportunistic salpingectomy at the time of elective laparoscopic cholecystectomy will be performed in study group, while the control group undergo cholecystectomy without salpingectomy. | Procedure or surgery | Experimental group |
| CholecystectomyCholezystectomy as controll group | Procedure or surgery | Control group, Experimental group |
Primary outcome
Postoperative complications assesed with Comprehensive complication index.
Time frame: within 6 weeks after surgery
This will be the primary outcome measure, encompassing any complications assessed with Comprehensive Complication Index. The range between 0 and 100. The higher score means more complications.
2 secondary outcomes
Operating time
Time frame: Operating time in minutes during surgical procedure
Length of hospital stay
Time frame: Length of hospital stay: The number of days patients remain hospitalized after surgery untill discharge assedd at discharge (assessed at around 5 days).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dilmurodjon MDE Eshmuminov, MD principal investigator
Univercity hospital zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Opportunistic salpingectomy and Cholecystectomy in people with Ovarian Cancer and Cholecystolithiasis, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative complications assesed with Comprehensive complication index. (time frame: within 6 weeks after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.